Pharmaceutical

AZD-9550 by AstraZeneca for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval

AZD-9550 is under clinical development by AstraZeneca and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Dec 26, 2023 - 18:00
AZD-9550 is under clinical development by AstraZeneca and currently in Phase I for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Read the original article

Tags:

Previous Article

ADRX-0706 by Adcentrx Therapeutics for Head And Neck Squamous Cell Carcinoma (HN...

Next Article

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE A...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Survey: Confusion over key requirements means clinical trials aren’t registered and results aren’t reported

STAT+: Survey: Confusion over key requirements means cl...

Jan 16, 2024

A scholar of the patient ‘revolution’ tracks the arc from powerlessness to influence

A scholar of the patient ‘revolution’ tracks the arc fr...

Feb 5, 2024

STAT+: Lasers, cardiology, clinical trials: 2023’s top private equity targets

STAT+: Lasers, cardiology, clinical trials: 2023’s top ...

Feb 9, 2024